AOD-9604
HGH Fragment — Targeted Fat Metabolism
Molecular Data
- Formula
- C78H123N23O23S2
- Molecular Weight
- 1815.1 g/mol
01
Overview
AOD-9604 (Advanced Obesity Drug 9604) is a modified fragment of the C-terminus of human growth hormone (hGH), spanning amino acids 176-191 with an added tyrosine at the N-terminal. It was developed specifically to isolate and amplify the fat-burning properties of HGH without the side effects of full-length HGH such as insulin resistance or cell proliferation.
02
Mechanism of Action
AOD-9604 mimics the way natural growth hormone regulates fat metabolism. It stimulates lipolytic activity in adipocytes via β3-adrenergic receptor mechanisms and inhibits the conversion of non-fatty food into body fat (lipogenesis). Its mechanism is distinct from the growth-promoting IGF-1-mediated pathways of full-length hGH.
03
Research Highlights
Clinical trials in obese subjects showed significant body fat reduction vs. placebo
Cartilage repair studies at Monash University show chondrocyte regeneration potential
Long-term safety studies show no adverse effects on glucose metabolism or IGF-1 levels
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue, typically once daily. Research protocols often administer on an empty stomach, morning or pre-exercise.
Dosage Guidelines
Cycle Length
4–12 weeks; clinical trials evaluated 12-week administration.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
2 mL added to a 5 mg vial
Concentration
2.5 mg/mL (2,500 mcg/mL)
Storage
Refrigerate at 2–8 °C; protect from light. Discard 30 days after reconstitution.
Notes
AOD-9604 is a fragment of hGH (177–191) optimized for lipolysis without IGF-1 elevation. A 250 mcg dose equals 10 units on a U-100 syringe.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
AOD-9604 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
AOD-9604 Knowledge Graph
Explore how AOD-9604 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
AOD-9604 — Common Research Questions
What is AOD-9604?
AOD-9604 (Advanced Obesity Drug 9604) is a modified fragment of the C-terminus of human growth hormone (hGH), spanning amino acids 176-191 with an added tyrosine at the N-terminal. It was developed sp... AOD-9604 belongs to the Weight Loss research category and is studied for its hgh fragment — targeted fat metabolism.
How does AOD-9604 work?
AOD-9604 mimics the way natural growth hormone regulates fat metabolism. It stimulates lipolytic activity in adipocytes via β3-adrenergic receptor mechanisms and inhibits the conversion of non-fatty food into body fat (lipogenesis). Its mechanism is distinct from the growth-promoting IGF-1-mediated pathways of full-length hGH.
What are the key research benefits of AOD-9604?
Targeted lipolysis (fat breakdown) stimulation. Inhibition of lipogenesis (fat formation). No effect on blood glucose or insulin sensitivity. No promotion of cell division or tumor growth. Cartilage and bone repair properties in research. Metabolically neutral outside of fat tissue.
What is the molecular structure of AOD-9604?
AOD-9604 has the molecular formula C78H123N23O23S2 and a molecular weight of 1815.1 g/mol. This structural information is important for researchers studying receptor binding and pharmacokinetics.
What does the research say about AOD-9604?
Clinical trials in obese subjects showed significant body fat reduction vs. placebo Cartilage repair studies at Monash University show chondrocyte regeneration potential Long-term safety studies show no adverse effects on glucose metabolism or IGF-1 levels These findings are based on preclinical and clinical research. AOD-9604 is a research compound and these studies do not constitute medical advice.
Is AOD-9604 FDA approved?
No. AOD-9604 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does AOD-9604 belong to?
AOD-9604 belongs to the Weight Loss category, which focuses on compounds studied for their roles in metabolic regulation, growth hormone signaling, and targeted adipose tissue reduction. You can explore more compounds in this category on the Weight Loss pillar page.
Related Articles
Tesamorelin: Clinical Data for Visceral Fat Reduction
Phase III trial data showing 15-18% visceral fat reduction and the FDA approval rationale for Egrifta®.
AOD-9604: Lipolysis Without Growth Effects
How AOD-9604's C-terminus fragment of HGH stimulates lipolysis without the growth-promoting effects of full-length HGH.
CJC-1295 + Ipamorelin: Synergistic GH Secretagogue Research
Examining the complementary mechanisms of CJC-1295 (GHRH analogue) and Ipamorelin (ghrelin mimetic) in research settings.
Scientific References
Stier et al. — "AOD-9604: HGH fragment for fat metabolism" (Obesity, 2006)
Monash University — Cartilage repair studies, 2008
Clinical trials in obese subjects showed significant body fat reduction vs. placebo
Cartilage repair studies at Monash University show chondrocyte regeneration potential
Long-term safety studies show no adverse effects on glucose metabolism or IGF-1 levels